Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data

WHO has targeted that medicines to prevent recurrent cardiovascular disease be available in 80% of communities and used by 50% of eligible individuals by 2025. We have previously reported that use of these medicines is very low, but now aim to assess how such low use relates to their lack of availab...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet (British edition) Ročník 387; číslo 10013; s. 61 - 69
Hlavní autori:	Khatib, Rasha, McKee, Martin, Shannon, Harry, Chow, Clara, Rangarajan, Sumathy, Teo, Koon, Wei, Li, Mony, Prem, Mohan, Viswanathan, Gupta, Rajeev, Kumar, Rajesh, Vijayakumar, Krishnapillai, Lear, Scott A, Diaz, Rafael, Avezum, Alvaro, Lopez-Jaramillo, Patricio, Lanas, Fernando, Yusoff, Khalid, Ismail, Noorhassim, Kazmi, Khawar, Rahman, Omar, Rosengren, Annika, Monsef, Nahed, Kelishadi, Roya, Kruger, Annamarie, Puoane, Thandi, Szuba, Andrzej, Chifamba, Jephat, Temizhan, Ahmet, Dagenais, Gilles, Gafni, Amiram, Yusuf, Salim
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 02.01.2016 Elsevier Limited
Predmet:	Adrenergic beta-Antagonists - economics Adrenergic beta-Antagonists - supply & distribution Adrenergic beta-Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - economics Angiotensin-Converting Enzyme Inhibitors - supply & distribution Angiotensin-Converting Enzyme Inhibitors - therapeutic use Argentina Aspirin - economics Aspirin - supply & distribution Aspirin - therapeutic use Bangladesh Brazil Canada Cardiovascular Agents - economics Cardiovascular Agents - supply & distribution Cardiovascular Agents - therapeutic use Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - drug therapy Chile China Clinical Medicine Colombia Community involvement Costs Developed Countries Developing Countries Disease prevention Drug Costs Enzyme inhibitors Epidemiology Family Characteristics Health care access Health risk assessment Households Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Income India Internal Medicine Iran Klinisk medicin Low income areas Malaysia Pakistan Pharmaceutical industry Pharmacies Platelet Aggregation Inhibitors - economics Platelet Aggregation Inhibitors - supply & distribution Platelet Aggregation Inhibitors - therapeutic use Poland Preventive medicine Rural areas Rural Population Secondary Prevention South Africa Statins Sweden Turkey United Arab Emirates Urban areas Urban Population Zimbabwe Colombia Argentina Malaysia United Arab Emirates India Canada Bangladesh Sweden Pakistan Turkey Iran China Brazil Poland South Africa Zimbabwe Chile ANE, France Canada, Ontario Germany
ISSN:	0140-6736, 1474-547X, 1474-547X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!